

(19) World Intellectual Property
Organization
International Bureau



INTERNATIONAL BUREAU OF PATENT COOPERATION
35, rue de la Harpe, CH-1015, Genève, Suisse
P.O. Box 6809, CH-1211, Genève, Suisse
P.O. Box 18, Armonia, D.C. 20740, USA
P.O. Box 17, Ginebra, España
P.O. Box 17, Ginebra, Paraguay
P.O. Box 17, Ginebra, Uruguay
P.O. Box 17, Ginebra, Venezuela

(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/044266 A1

(51) International Patent Classification⁷: A61K 31/44,
C07D 213/16, 213/24, 213/26, 213/30, A61P 1/04

(74) Agents: BENT, Stephen A. et al.; Foley & Lardner LLP,
Washington Harbour, 3000 K Street, NW, Suite 500, Wash-
ington, District of Columbia 20007-5101 (US).

(21) International Application Number:
PCT/US2004/034517

(22) International Filing Date: 20 October 2004 (20.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/560,715 31 October 2003 (31.10.2003) US

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(71) Applicants (for all designated States except US): AS-
TRAZENECA AB [SE/SE]; SE-151, 85 Södertälje,
S-SE-151 Södertälje (SE). NPS PHARMACEUTICALS,
INC. [US/US]; 420 Chipeta Way, Salt Lake City, Utah
84108 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BACH, Peter
[SE/SE]; AstraZeneca R & D Molndal, 83 Molndal,
S-SE-431 Molndal (SE). BAUER, Udo [SE/SE]; As-
traZeneca R & D Molndal, 83 Molndal, S-SE-431 Molndal
(SE). NILSSON, Karolina [SE/SE]; AstraZeneca R & D
Molndal, 83 Molndal, S-SE-431 Molndal (SE). WÄLL-
BERG, Andreas [SE/SE]; AstraZeneca R & D Molndal,
83 Molndal, S-SE-431 Molndal (SE).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ALKYNES I

(57) Abstract: The present invention is directed to novel compounds of formula (I), to a process for their preparation, their use
in therapy and pharmaceutical compositions comprising the novel compounds. The novel compounds are useful in therapy, and in
particular for the treatment of gastroesophageal reflux disease (GERD).

WO 2005/044266 A1